| Literature DB >> 27650456 |
Noriyuki Hirahara1, Takeshi Matsubara2, Yoko Mizota2, Shuichi Ishibashi2, Yoshitsugu Tajima2.
Abstract
BACKGROUND: Several inflammatory response biomarkers, including lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been reported to predict survival in various cancers. The aim of this study is to evaluate the clinical value of these biomarkers in patients undergoing curative resection for esophageal cancer.Entities:
Keywords: Esophageal cancer; Lymphocyte to monocyte ratio (LMR); Neutrophil to lymphocyte ratio (NLR); Platelet lymphocyte ratio (PLR); Prognostic predictor
Mesh:
Substances:
Year: 2016 PMID: 27650456 PMCID: PMC5028997 DOI: 10.1186/s12893-016-0179-5
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Relationships between LMR, NLR, PLR and clinicopathologic features of 147 all patients
| Characteristics | Total patients | LMR | NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <4 | ≥4 |
| 1.6< | ≥1.6 |
| 147< | ≥147 |
| ||
| Age (years) | 65.8 ± 7.4 | 65.7 ± 8.2 | 0.934 | 65.4 ± 8.0 | 65.9 ± 7.9 | 0.72 | 66.8 ± 8.1 | 64.6 ± 7.6 | 0.097 | |
| Gender | 0.052 | 0.163 | 0.562 | |||||||
| Male | 132 | 61 | 71 | 31 | 101 | 72 | 60 | |||
| Female | 15 | 3 | 12 | 6 | 9 | 7 | 8 | |||
| WBC | 6082.2 ± 2153.2 | 5844.3 ± 1788.2 | 0.466 | 5284.1 ± 1667.3 | 6171.2 ± 1996.5 | 0.016 | 6190.9 ± 1723.0 | 5665.6 ± 2167.2 | 0.104 | |
| Neutrophil | 3944.7 ± 1804.6 | 3412.8 ± 1470.4 | 0.051 | 2491.0 ± 948.3 | 4032.3 ± 1643.7 | <0.0001 | 3509.3 ± 1300.5 | 3801.3 ± 1960.9 | 0.283 | |
| Lymphocyte | 1322.0 ± 546.4 | 1942.5 ± 584.5 | <0.0001 | 2187.6 ± 658.6 | 1499.0 ± 541.8 | <0.0001 | 2029.2 ± 586.3 | 1257.7 ± 426.2 | <0.0001 | |
| Monocyte | 546.8 ± 211.3 | 328.7 ± 111.1 | <0.0001 | 379.0 ± 161.3 | 438.7 ± 203.3 | 0.1074 | 418.2 ± 171.3 | 430.0 ± 220.2 | 0.714 | |
| Platelet | 236.6 ± 79.2 | 226.9 ± 66.2 | 0.42 | 231.0 ± 76.9 | 231.2 ± 70.7 | 0.987 | 203.5 ± 49.2 | 263.2 ± 80.9 | <0.0001 | |
| Location of tumor | 0.09 | 0.313 | 0.042 | |||||||
| Ce | 6 | 5 | 1 | 1 | 5 | 0 | 6 | |||
| Ut | 8 | 4 | 4 | 0 | 8 | 5 | 3 | |||
| Mt | 65 | 29 | 36 | 20 | 45 | 32 | 33 | |||
| Lt | 52 | 23 | 29 | 11 | 41 | 31 | 21 | |||
| Ae | 16 | 3 | 13 | 5 | 11 | 11 | 5 | |||
| Tumor size (mm) | 4.9 ± 1.9 | 3.9 ± 2.7 | 0.014 | 3.8 ± 2.8 | 4.5 ± 2.3 | 0.134 | 4.0 ± 2.5 | 4.8 ± 2.3 | 0.056 | |
| Depth of tumor | 0.0007 | 0.002 | 0.06 | |||||||
| T1a-1b | 66 | 20 | 46 | 18 | 48 | 40 | 26 | |||
| 2 | 12 | 2 | 10 | 8 | 4 | 9 | 3 | |||
| 3 | 56 | 33 | 23 | 8 | 48 | 26 | 30 | |||
| 4a-4b | 13 | 9 | 4 | 3 | 10 | 4 | 9 | |||
| Lymph node metastasis | 0.2732 | 0.1532 | 0.0639 | |||||||
| N0 | 79 | 30 | 49 | 22 | 57 | 43 | 36 | |||
| N1 | 42 | 19 | 23 | 12 | 30 | 25 | 17 | |||
| N2 | 12 | 8 | 4 | 3 | 9 | 8 | 4 | |||
| N3 | 14 | 7 | 7 | 0 | 14 | 3 | 11 | |||
| Pathological stage | 0.0002 | 0.1338 | 0.3497 | |||||||
| 1a-1b | 59 | 14 | 45 | 20 | 39 | 36 | 23 | |||
| 2a-2b | 33 | 21 | 12 | 6 | 27 | 16 | 17 | |||
| 3a-3c | 55 | 29 | 26 | 11 | 44 | 27 | 28 | |||
| Operation time (min) | 644.8 ± 162.2 | 663.5 ± 159.2 | 0.4843 | 655.9 ± 177.2 | 655.2 ± 155.0 | 0.9798 | 676.5 ± 149.0 | 630.8 ± 170.2 | 0.0845 | |
| Intraoperative blood loss (ml) | 751.8 ± 622.8 | 581.6 ± 633.4 | 0.1059 | 568.8 ± 511.1 | 684.9 ± 667.8 | 0.3359 | 598.5 ± 633.1 | 722.2 ± 629.7 | 0.2384 | |
| SCC antigen | 1.19 ± 1.06 | 1.12 ± 1.12 | 0.7208 | 1.04 ± 1.12 | 1.19 ± 1.08 | 0.7643 | 1.05 ± 0.91 | 1.27 ± 1.26 | 0.8858 | |
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio
Prognostic factors for cancer-specific survival in 147 patients with esophageal cancer
| Variables | Patients ( | Category or characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95 % CI |
| HR | 95 % CI |
| |||
| Gender | 15/132 | (female/male) | 0.942 | 0.406–2.740 | 0.9007 | |||
| Age | 46/101 | (70</≥70) | 1.427 | 0.742–2.639 | 0.2771 | |||
| pStage | 92/55 | (1,2/3) | 4.876 | 2.625–9.420 | <0.0001 | 4.19 | 2.146–8.562 | <0.0001 |
| Tumor size | 45/102 | (3</≥3) | 3.405 | 1.548–8.981 | 0.0014 | 1.433 | 0.580–4.056 | 0.4493 |
| Operation time | 99/48 | (600</≥600) | 2.041 | 1.116–3.741 | 0.0209 | 1.425 | 0.757–2.681 | 0.2699 |
| Intraoperative blood loss | 72/75 | (500</≥500) | 1.321 | 0.723–2.463 | 0.3663 | |||
| LMR | 83/64 | (≥4.0/4.0<) | 2.829 | 1.537–5.378 | 0.0008 | 2.372 | 1.198–4.840 | 0.0129 |
| NLR | 37/110 | (≥1.6/1.6<) | 1.469 | 0.753–2.734 | 0.2494 | |||
| PLR | 79/68 | (147</≥147) | 2.013 | 1.100–3.783 | 0.0232 | 1.12 | 0.611–2.404 | 0.5999 |
| SCC antigen | 109/38 | (1.5</≥1.5) | 1.3 | 0.603–2.564 | 0.4842 | |||
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI confidence interval
Relationships between LMR, NLR, PLR and clinicopathologic features of 101 nonelderly patients
| Characteristics | Total patients | LMR | NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <4 | ≥4 |
| 1.6< | ≥1.6 |
| 147< | ≥147 |
| ||
| Age (years) | 61.9 ± 5.2 | 61.6 ± 5.6 | 0.7778 | 61.1 ± 5.8 | 61.9 ± 5.3 | 0.7249 | 62.4 ± 5.2 | 60.8 ± 5.5 | 0.1294 | |
| Gender | 0.1283 | 0.2392 | 0.1171 | |||||||
| Male | 91 | 41 | 50 | 21 | 70 | 51 | 40 | |||
| Female | 10 | 2 | 8 | 4 | 6 | 3 | 7 | |||
| WBC | 6261.2 ± 2234.8 | 5951.4 ± 1747.8 | 0.7819 | 5654.4 ± 1725.4 | 6224.3 ± 2028.8 | 0.2101 | 6242.2 ± 1660.6 | 5900.6 ± 287.0 | 0.3863 | |
| Neutrophil | 4020.2 ± 1757.4 | 3506.3 ± 1522.4 | 0.9402 | 2645.3 ± 978.7 | 4080.3 ± 1659.8 | <0.0001 | 3481.2 ± 1252.0 | 4005.4 ± 1969.1 | 0.109 | |
| Lymphocyte | 1352.8 ± 621.1 | 1964.2 ± 584.6 | <0.0001 | 2362.7 ± 651.4 | 1487.2 ± 520.4 | <0.0001 | 2068.7 ± 601.1 | 1284.7 ± 473.7 | <0.0001 | |
| Monocyte | 574.3 ± 223.8 | 336.1 ± 109.6 | <0.0001 | 395.8 ± 163.2 | 451.3 ± 215.8 | 0.2417 | 438.1 ± 172.2 | 436.9 ± 238.6 | 0.9756 | |
| Platelet | 230.1 ± 76.1 | 233.0 ± 70.2 | 0.8422 | 215.2 ± 64.4 | 237.2 ± 74.5 | 0.9051 | 205.7 ± 47.3 | 261.7 ± 84.3 | <0.0001 | |
| Location of tumor | 0.0169 | 0.5489 | 0.1445 | |||||||
| Ce | 4 | 4 | 0 | 0 | 4 | 0 | 4 | |||
| Ut | 4 | 3 | 1 | 0 | 4 | 3 | 1 | |||
| Mt | 49 | 23 | 26 | 14 | 35 | 24 | 25 | |||
| Lt | 31 | 11 | 20 | 8 | 23 | 19 | 12 | |||
| Ae | 13 | 2 | 11 | 3 | 10 | 8 | 5 | |||
| Tumor size (mm) | 4.9 ± 2.1 | 3.9 ± 2.8 | 0.0309 | 3.4 ± 2.7 | 4.6 ± 2.5 | 0.0452 | 4.0 ± 2.8 | 4.7 ± 2.2 | 0.2116 | |
| Depth of tumor | 0.0093 | 0.0018 | 0.0943 | |||||||
| T1a-1b | 44 | 12 | 32 | 13 | 31 | 29 | 15 | |||
| 2 | 6 | 1 | 5 | 5 | 1 | 4 | 2 | |||
| 3 | 40 | 23 | 17 | 5 | 35 | 17 | 23 | |||
| 4a-4b | 11 | 7 | 4 | 2 | 9 | 4 | 7 | |||
| Lymph node metastasis | 0.5691 | 0.1307 | 0.3183 | |||||||
| N0 | 56 | 22 | 34 | 18 | 38 | 32 | 24 | |||
| N1 | 28 | 13 | 15 | 6 | 22 | 16 | 12 | |||
| N2 | 6 | 4 | 2 | 1 | 5 | 3 | 3 | |||
| N3 | 11 | 4 | 7 | 0 | 11 | 3 | 8 | |||
| Pathological stage | 0.0003 | 0.0032 | 0.1024 | |||||||
| 1a-1b | 41 | 9 | 32 | 17 | 24 | 27 | 14 | |||
| 2a-2b | 20 | 15 | 5 | 1 | 19 | 8 | 12 | |||
| 3a-3c | 40 | 19 | 21 | 7 | 33 | 19 | 21 | |||
| Operation time (min) | 617.8 ± 142.7 | 666.4 ± 148.0 | 0.101 | 643.33 ± 151.1 | 646.5 ± 146.8 | 0.9246 | 680.2 ± 147.9 | 606.0 ± 137.2 | 0.107 | |
| Intraoperative blood loss (ml) | 727.9 ± 578.1 | 538.5 ± 523.1 | 0.0543 | 616.4 ± 567.6 | 620.1 ± 551.2 | 0.9772 | 563.0 ± 531.4 | 683.7 ± 574.5 | 0.2753 | |
| SCC antigen | 1.01 ± 0.76 | 1.20 ± 1.26 | 0.3828 | 1.11 ± 1.26 | 1.11 ± 1.02 | 0.9667 | 1.04 ± 0.97 | 1.20 ± 1.19 | 0.465 | |
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio
Univariate and multivariate analysis of prognostic factors in 101 non-elderly patients with esophageal cancer
| Variables | Patients ( | Category or characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95 % CI |
| HR | 95 % CI |
| |||
| Gender | 10/91 | (female/male) | 0.608 | 0.233–20.78 | 0.388 | |||
| pStage | 61/40 | (1,2/3) | 5.022 | 2.321–11.715 | <0.0001 | 4.009 | 1.731–10.162 | 0.001 |
| Tumor size | 34/67 | (3</≥3) | 8.34 | 2.491–51.782 | 0.0001 | 3.115 | 0.788–20.674 | 0.1114 |
| Operation time | 67/34 | (600</≥600) | 2.219 | 1.048–4.752 | 0.0374 | 1.109 | 0.490–2.540 | 0.803 |
| Intraoperative blood loss | 49/52 | (500</≥500) | 1.53 | 0.723–3.373 | 0.2679 | |||
| LMR | 58/43 | (≥4/4<) | 5.076 | 2.259–12.909 | <0.0001 | 4.553 | 1.856–12.516 | 0.0007 |
| NLR | 25/76 | (≥1.6/1.6<) | 1.593 | 0.656–4.750 | 0.322 | |||
| PLR | 54/47 | (147</≥147) | 2.475 | 1.160–5.592 | 0.0189 | 1.163 | 0.499–2.845 | 0.5999 |
| SCC antigen | 76/25 | (1.5</≥1.5) | 0.915 | 0.305–2.244 | 0.857 | |||
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI confidence interval
Relationships between LMR, NLR, PLR and clinicopathologic features of 46 elderly patients
| Characteristics | Total patients | LMR | NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <4 | ≥4 |
| 1.6< | ≥1.6 |
| 147< | ≥147 |
| ||
| Age (years) | 74.0 ± 3.8 | 75.4 ± 4.4 | 0.8781 | 74.3 ± 3.0 | 75.0 ± 4.5 | 0.6094 | 76.2 ± 4.3 | 73.1 ± 3.3 | 0.012 | |
| Gender | 0.2226 | 0.453 | 0.2226 | |||||||
| Male | 41 | 20 | 21 | 10 | 31 | 21 | 20 | |||
| Female | 5 | 1 | 4 | 2 | 3 | 4 | 1 | |||
| WBC | 5715.7 ± 1976.4 | 5596.0 ± 1891.6 | 0.835 | 4512.5 ± 1281.2 | 6052.4 ± 1946.8 | 0.0146 | 6080.0 ± 1881.6 | 5139.5 ± 1858.8 | 0.0966 | |
| Neutrophil | 3790.0 ± 1932.6 | 3195.8 ± 1346.0 | 0.2271 | 2169.4 ± 828.4 | 3925.1 ± 1626.7 | 0.0009 | 3570.0 ± 1424.7 | 3344.5 ± 1909.4 | 0.649 | |
| Lymphocyte | 1258.9 ± 352.0 | 1892.1 ± 593.0 | <0.0001 | 1822.8 ± 528.1 | 1525.4 ± 594.0 | 0.1327 | 1943.9 ± 555.2 | 1197.2 ± 294.4 | <0.0001 | |
| Monocyte | 490.2 ± 174.3 | 311.6 ± 115.0 | 0.0001 | 344.1 ± 158.3 | 410.5 ± 171.8 | 0.2469 | 375.1 ± 164.4 | 414.7 ± 176.4 | 0.4351 | |
| Platelet | 250.0 ± 85.7 | 212.8 ± 54.3 | 0.0805 | 263.8 ± 92.6 | 217.8 ± 60.4 | 0.0563 | 198.8 ± 53.8 | 266.6 ± 74.7 | 0.0009 | |
| Location of tumor | 0.6568 | 0.1274 | 0.2753 | |||||||
| Ce | 2 | 1 | 1 | 1 | 1 | 0 | 2 | |||
| Ut | 4 | 1 | 3 | 0 | 4 | 2 | 2 | |||
| Mt | 16 | 6 | 10 | 6 | 10 | 8 | 8 | |||
| Lt | 21 | 12 | 9 | 3 | 18 | 12 | 9 | |||
| Ae | 3 | 1 | 2 | 2 | 1 | 3 | 0 | |||
| Tumor size (mm) | 4.9 ± 1.5 | 3.9 ± 2.5 | 0.0987 | 4.6 ± 3.2 | 4.3 ± 1.7 | 0.6459 | 3.9 ± 1.8 | 4.9 ± 2.4 | 0.0987 | |
| Depth of tumor | 0.0716 | 0.3997 | 0.2032 | |||||||
| T1a-1b | 22 | 8 | 14 | 5 | 17 | 11 | 11 | |||
| 2 | 6 | 1 | 5 | 3 | 3 | 5 | 1 | |||
| 3 | 16 | 10 | 6 | 3 | 13 | 9 | 7 | |||
| 4a-4b | 2 | 2 | 0 | 1 | 1 | 0 | 2 | |||
| Lymph node metastasis | 0.1229 | 0.2441 | 0.0875 | |||||||
| N0 | 23 | 8 | 15 | 4 | 19 | 11 | 12 | |||
| N1 | 14 | 6 | 8 | 6 | 8 | 9 | 5 | |||
| N2 | 6 | 4 | 2 | 2 | 4 | 5 | 1 | |||
| N3 | 3 | 3 | 0 | 0 | 3 | 0 | 3 | |||
| Pathological stage | 0.0825 | 0.3939 | 0.8129 | |||||||
| 1a-1b | 18 | 5 | 13 | 3 | 15 | 9 | 9 | |||
| 2a-2b | 13 | 6 | 7 | 5 | 8 | 8 | 5 | |||
| 3a-3c | 15 | 10 | 5 | 4 | 11 | 8 | 7 | |||
| Operation time (min) | 700.0 ± 187.8 | 656.8 ± 185.7 | 0.4385 | 682.3 ± 227.8 | 674.5 ± 172.6 | 0.9021 | 668.5 ± 154.0 | 686.2 ± 221.6 | 0.7515 | |
| Intraoperative blood loss (ml) | 800.7 ± 718.7 | 681.5 ± 840.3 | 0.3057 | 469.8 ± 368.8 | 829.9 ± 866.8 | 0.1723 | 675.2 ± 818.5 | 808.2 ± 746.9 | 0.2854 | |
| SCC antigen | 1.56 ± 1.44 | 0.96 ± 0.68 | 0.0342 | 0.90 ± 0.80 | 1.35 ± 1.21 | 0.2379 | 1.07 ± 0.78 | 1.42 ± 1.43 | 0.2961 | |
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio
Univariate and multivariate analysis of prognostic factors in 46 elderly patients with esophageal cancer
| Variables | Patients ( | Category or characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95 % CI |
| HR | 95 % CI |
| |||
| Gender | 5/41 | (female/male) | 3.114 | 0.611–56.892 | 0.201 | |||
| pStage | 31/15 | (1,2/3) | 5.22 | 1.824–16.080 | 0.0023 | 5.22 | 1.824–16.080 | 0.0023 |
| Tumor size | 11/35 | (3</≥3) | 0.976 | 0.333–3.529 | 0.9666 | |||
| Operation time | 32/14 | (600</≥600) | 1.761 | 0.615–4.929 | 0.2822 | |||
| Intraoperative blood loss | 23/23 | (500</≥500) | 0.981 | 0.349–2.820 | 0.9707 | |||
| LMR | 25/21 | (≥4/4<) | 1.118 | 0.368–3.175 | 0.837 | |||
| NLR | 12/34 | (≥1.6/1.6<) | 0.853 | 0.464–1.535 | 0.718 | |||
| PLR | 25/21 | (147</≥147) | 1.3 | 0.464–3.712 | 0.616 | |||
| SCC antigen | 33/13 | (1.5</≥1.5) | 2.261 | 0.689–6.565 | 0.167 | |||
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI, confidence interval
Fig. 1Kaplan-Meier survival curves showing CSS after curative esophagectomy in overall patients with esophageal cancer. a LMR. b NLR. c PLR
Fig. 2Kaplan-Meier survival curves showing CSS after curative esophagectomy in non-elderly patients with esophageal cancer. a LMR. b NLR. c PLR
Fig. 3Kaplan-Meier survival curves showing CSS after curative esophagectomy in elderly patients with esophageal cancer. a LMR. b NLR. c PLR